BioSpace News Archive

Initial data anticipated in the third quarter of 2021 Top-line data from the ongoing Phase 1b proof of concept clinical trial in relapsed or refractory multiple myeloma patients anticipated in the second half of 2021

Company reports first quarter total revenue of $12.0 million First quarter 2021 XHANCE net revenue of $11.0 million increased 55% compared to first quarter 2020 Conference call and webcast to be held today at 8:00 a.m. Eastern Time

Chiasma, Inc. (NASDAQ: CHMA), a commercial stage biopharmaceutical company utilizing its delivery platform technology to develop and commercialize oral therapies to reduce the burden of chronic injections for people with rare diseases, as evidenced by its initiation of a phased U.S. commercial launch of MYCAPSSA® as the first oral therapy for treatment of acromegaly, today announced financial results for the first quarter ended March 31, 2021

Trevena, Inc. (Nasdaq: TRVN) , a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that it will release its financial results for the first quarter ended March 31, 2021, prior to the market open on Thursday, May 6, 2021. Company management will host a conference call and webcast to discuss its financial results

ANJESO ® Demonstrates Continued Progress with Launch; Growth in End-User Unit Sales Increased 40% in Q1 compared to Q4’20 Average Sales per Account Increased 30% in Q1 compared to Q4’20 Richard S. Casten Strengthens Management Team in Chief Financial Officer Role Management to Host Investor Conference Call and Webcast Today at 8:00 a.m. ET

- Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic® platform, today announced a clinical development update for CERPASS, its registration-directed global randomized Phase 2 clinical trial of RP1 in combination with Libtayo® (cemiplimab)

Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce first quarter financial results and provide a business update on Wednesday, May 12, 2021. The company will host a conference call and live webcast at 4:30 p.m. Eastern Daylight Time on the same day.

Genesis Software Innovations “GSI,” a company that has created an innovative foundational platform solution in the orthopedic space, announced today that they have received FDA clearance for their PreView™ 3D Shoulder Arthroplasty Planning Software

On track to achieve 2021 guidance Webcast today, May 5, 2021, at 11:30 a.m. Eastern Time

Pharmaceutical industry veteran Joe Jimenez appointed Board Chair Cynthia Butitta joins as Independent Director